• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences’ Advanced Regenerative Technology Featured in European Heart Journal

April 7, 2014 By Celyad

Editorial highlights next generation stem cell solutions optimized for heart failure therapy 

Mont-Saint-Guibert, Belgium, – Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today the referencing in the European Heart Journal, the official journal of the European Society of Cardiology, of lineage-specified cardioreparative stem cells as next generation regenerative biotherapeutics.

The editorial sets out the principles of regenerative cardiology, conceived to halt or reverse disease progression. As the heart has a limited self-renewal capacity, stem cell therapies are applied essentially as adjuvants to standard of care with the goal of fortifying reparative mechanisms. The editorial emphasizes that the inter-trial unevenness and inter-patient variability observed to date with conventional stem cell options has prompted the pursuit of optimization strategies, and lists optimization modalities under consideration, such as the principle to condition the myocardial environment prior to cell delivery, the principle to match regenerative cell source with the target organ, and the principle of rational design of cardioreparative biotherapeutics equipped with an upgraded regenerative potential.

The Cardio3 Biosciences’ C-Cure® product is the first-in-class cardioreparative biotherapeutics derived by the method of lineage-specification for use in heart failure. In the Phase II C-CURE clinical trial, heart failure patients were treated with C-Cure® which consists of patient-derived mesenchymal stem cells oriented into lineage-specified cardiogenic progenitor (cardiopoietic) cells. The C-CURE study indicates that the use of cardiopoietic cells is feasible and safe and documents significant benefit on Left Ventricular Ejection Fraction, a measure of heart function, versus baseline compared to no change for the control group treated with standard of care. C-Cure® is now tested in a Phase III study in Europe and Israel (CHART-1) and has been authorized by the FDA to be tested in the U.S (CHART-2). These phase III therapeutic studies highlight advances in regenerative science.

Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “Recognition in this editorial published in the prestigious European Heart Journal underscores Cardio3 BioSciences’ continuous advances and leadership in regenerative medicine, progressively bringing innovative science-driven therapeutic options to patients. By choosing the route of lineage specification, we lay the foundation for future standard of care in cardiology.”

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Cardiology, Clinical

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy